317 related articles for article (PubMed ID: 26806497)
21. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
23. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
24. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Matsuda A; Tohyama K; Taniwaki M; Takeshita K; Takatoku M; Ozawa K
Int J Hematol; 2009 Oct; 90(3):353-360. PubMed ID: 19705057
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Raza A; Reeves JA; Feldman EJ; Dewald GW; Bennett JM; Deeg HJ; Dreisbach L; Schiffer CA; Stone RM; Greenberg PL; Curtin PT; Klimek VM; Shammo JM; Thomas D; Knight RD; Schmidt M; Wride K; Zeldis JB; List AF
Blood; 2008 Jan; 111(1):86-93. PubMed ID: 17893227
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
[TBL] [Abstract][Full Text] [Related]
28. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Mossner M; Jann JC; Nowak D; Platzbecker U; Giagounidis A; Götze K; Letsch A; Haase D; Shirneshan K; Braulke F; Schlenk RF; Haferlach T; Schafhausen P; Bug G; Lübbert M; Ganser A; Büsche G; Schuler E; Nowak V; Pressler J; Obländer J; Fey S; Müller N; Lauinger-Lörsch E; Metzgeroth G; Weiß C; Hofmann WK; Germing U; Nolte F
Leukemia; 2016 Sep; 30(9):1956-9. PubMed ID: 27133825
[No Abstract] [Full Text] [Related]
29. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
31. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
[TBL] [Abstract][Full Text] [Related]
32. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
List A; Dewald G; Bennett J; Giagounidis A; Raza A; Feldman E; Powell B; Greenberg P; Thomas D; Stone R; Reeder C; Wride K; Patin J; Schmidt M; Zeldis J; Knight R;
N Engl J Med; 2006 Oct; 355(14):1456-65. PubMed ID: 17021321
[TBL] [Abstract][Full Text] [Related]
35. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
[TBL] [Abstract][Full Text] [Related]
36. Treatment of the 5q- syndrome.
Fenaux P; Kelaidi C
Hematology Am Soc Hematol Educ Program; 2006; ():192-8. PubMed ID: 17124060
[TBL] [Abstract][Full Text] [Related]
37. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
Raza A; Galili N; Mulford D; Smith SE; Brown GL; Steensma DP; Lyons RM; Boccia R; Sekeres MA; Garcia-Manero G; Mesa RA
J Hematol Oncol; 2012 Apr; 5():18. PubMed ID: 22546242
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
